HC Wainwright Has Positive Outlook for GALT Q2 Earnings

Galectin Therapeutics Inc. (NASDAQ:GALT) – Investment analysts at HC Wainwright boosted their Q2 2025 earnings per share estimates for shares of Galectin Therapeutics in a research note issued on Wednesday, April 2nd. HC Wainwright analyst E. Arce now expects that the company will post earnings of ($0.19) per share for the quarter, up from their previous forecast of ($0.21). HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Galectin Therapeutics’ current full-year earnings is ($0.73) per share. HC Wainwright also issued estimates for Galectin Therapeutics’ Q4 2025 earnings at ($0.26) EPS, FY2025 earnings at ($0.89) EPS, FY2026 earnings at ($1.11) EPS, FY2027 earnings at ($0.64) EPS and FY2028 earnings at ($1.06) EPS.

Separately, StockNews.com lowered Galectin Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, December 30th.

Galectin Therapeutics Trading Up 0.4 %

GALT stock opened at $1.33 on Monday. The firm has a market cap of $83.71 million, a PE ratio of -1.82 and a beta of 0.79. Galectin Therapeutics has a 1 year low of $0.73 and a 1 year high of $4.27. The company has a fifty day simple moving average of $1.46 and a 200 day simple moving average of $1.91.

Galectin Therapeutics (NASDAQ:GALT) last posted its earnings results on Monday, March 31st. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.03).

Institutional Investors Weigh In On Galectin Therapeutics

A number of large investors have recently added to or reduced their stakes in GALT. Sovran Advisors LLC bought a new position in shares of Galectin Therapeutics in the fourth quarter valued at approximately $240,000. Soltis Investment Advisors LLC acquired a new position in Galectin Therapeutics in the 3rd quarter valued at $387,000. Retirement Guys Formula LLC raised its holdings in Galectin Therapeutics by 143.4% in the 4th quarter. Retirement Guys Formula LLC now owns 155,343 shares of the company’s stock worth $200,000 after acquiring an additional 91,526 shares during the period. LPL Financial LLC lifted its position in Galectin Therapeutics by 69.6% during the 4th quarter. LPL Financial LLC now owns 138,928 shares of the company’s stock worth $179,000 after acquiring an additional 57,020 shares during the last quarter. Finally, Kovitz Investment Group Partners LLC bought a new stake in Galectin Therapeutics during the third quarter valued at about $117,000. Institutional investors own 11.68% of the company’s stock.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.